
News|Articles|November 2, 2026
Clinical trial news in pediatrics: October 2026
Author(s)Contemporary Pediatrics Staff
Fact checked by: Morgan Ebert, Executive Editor
A recap of the top pediatric clinical trial results and pipeline data readouts during October 2026.
Advertisement
Advertisement
October's pediatric clinical trial news came largely out of fall congress season — EADV, MDS, United European Gastroenterology Week, and ASN Kidney Week all generated late-breaking pediatric or adolescent data — spanning vitiligo, psoriasis, Tourette syndrome, ulcerative colitis, eosinophilic esophagitis, a rare bone disease, and sepsis-associated kidney injury. Most of the month's readouts extend follow-up on drugs that are already approved (or nearly so) for older patients or adults, and several rely on open-label extensions, post hoc analyses, or cross-study comparisons rather than placebo-controlled pediatric data.
Related to this article

Find out the 4 FDA decisions to watch in November 2026 for pediatric care.

Cenobamate sNDAs target PGTC seizures in patients ≥12 years and pediatric focal seizures; phase 3 PGTC data showed a 71.9% median reduction.

FDA approved Lupin's generic of Firdapse for LEMS in patients 6 years and older, but a patent settlement delays US marketing until at least 2035.

A recap of the top FDA approvals, regulatory decisions, and pipeline updates affecting pediatric care during October 2026.

In PROGRESS Cohort 2, zilurgisertib reduced total HO volume vs placebo at 24 weeks in children aged 6 to 11 with FOP, with no new HO lesions.

Registry data presented at ASN Kidney Week 2026 linked SCD-PED to higher 90-day survival vs historical controls in pediatric sepsis-associated AKI.

The FDA approved insulin icodec-abae for children 10+ with T2D, based on adult ONWARDS data and a single-dose pediatric pharmacokinetic study.
Advertisement
Advertisement
